Clinical Trials Logo

Healthy Participant clinical trials

View clinical trials related to Healthy Participant.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06087055 Completed - Healthy Participant Clinical Trials

Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants

Start date: May 12, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of GST-HG171/ritonavir in healthy participants.

NCT ID: NCT05450549 Completed - Healthy Participant Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants

Start date: July 14, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL919.

NCT ID: NCT05311865 Completed - Healthy Participant Clinical Trials

Transmission of Covid-19 During Clubbing Events in Closed Places

ITOC
Start date: September 4, 2021
Phase: N/A
Study type: Interventional

The ITOC study is a cluster randomised, controlled, multicentre trial in Paris region, France. The intervention is an 8-hour indoor clubbing event with no mask wearing, no social distancing, at maximum room capacity. 1,200 healthy volunteers aged 18-49 years and fully vaccinated will be included. Participants are recruited by group of up to 10, to be randomized 2:1 to experimental group (800 volunteers in a venue ) or control group (400 volunteers asked to stay at home). All participants will provide a salivary sample the day of experiment and seven days later. Participants will also answer surveys on the social and psychological impact of lockdown and indoor club closing, attitude towards vaccination, behaviour at risk of COVID-19 transmission during the day of the event (for both groups) as well as follow-up surveys on symptoms that participant may experience. Virological analyses include polymerase chain reaction (PCR) of salivary samples and air of the venue, investigating SARS-CoV-2 PCR.

NCT ID: NCT04962230 Completed - Healthy Participant Clinical Trials

Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir

Start date: July 15, 2021
Phase: Phase 1
Study type: Interventional

This is a drug-drug interaction study to assess the effects of a single dose of PF-07321332/ritonavir after multiple dose administrations of carbamazepine. Pharmacokinetic (PK) will be evaluated for PF-07321332 and ritonavir. Carbamazepine is being utilized as a cytochrome P450 3A4 (CYP3A4) inducer.

NCT ID: NCT04962022 Completed - Healthy Participant Clinical Trials

Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants

Start date: July 20, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of PF-07321332/ritonavir in healthy participants.